BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033-1039. [PMID: 28913966 DOI: 10.1002/pds.4297] [Cited by in Crossref: 176] [Cited by in F6Publishing: 185] [Article Influence: 35.2] [Reference Citation Analysis]
Number Citing Articles
1 Vincenzi B, Napolitano A, Comandone A, Sanfilippo R, Celant S, Olimpieri PP, Di Segni S, Russo P, Casali PG. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry. Int J Cancer 2023;152:761-8. [PMID: 36196483 DOI: 10.1002/ijc.34309] [Reference Citation Analysis]
2 Mukhina SM, Baranova MI, Balykina YE. HARPER — protocol template for real-world trials for evaluating treatment efficacy. MyRWD 2023;2:17-25. [DOI: 10.37489/2782-3784-myrwd-23] [Reference Citation Analysis]
3 Wang SV, Pottegård A, Crown W, Arlett P, Ashcroft DM, Benchimol EI, Berger ML, Crane G, Goettsch W, Hua W, Kabadi S, Kern DM, Kurz X, Langan S, Nonaka T, Orsini L, Perez-Gutthann S, Pinheiro S, Pratt N, Schneeweiss S, Toussi M, Williams RJ. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force. Pharmacoepidemiol Drug Saf 2023;32:44-55. [PMID: 36215113 DOI: 10.1002/pds.5507] [Reference Citation Analysis]
4 Wanner C, Schuchhardt J, Bauer C, Lindemann S, Brinker M, Kong SX, Kleinjung F, Horvat-Broecker A, Vaitsiakhovich T. Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database. J Nephrol 2023;36:45-54. [PMID: 35567698 DOI: 10.1007/s40620-022-01340-x] [Reference Citation Analysis]
5 Oehrlein EM, Schoch S, Burcu M, McBeth JF, Bright J, Pashos CL, Willke R, Love TR, Mattingly TJ 2nd, Perfetto EM; Patient-Centered Real-World Evidence Working Group. Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process. Value Health 2023;26:28-38. [PMID: 35863944 DOI: 10.1016/j.jval.2022.04.1738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Phillips VL, Xu J, Park A, Gantt S, Dedhia K. The cost-effectiveness of targeted screening for congenital cytomegalovirus in newborns compared to clinical diagnosis in the US. International Journal of Pediatric Otorhinolaryngology 2023. [DOI: 10.1016/j.ijporl.2023.111450] [Reference Citation Analysis]
7 Emanuela Zagni, Micol Frassi, Giuseppa Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Walter Grassi, Rosa Daniela Grembiale, Giuliana Guggino, Antonino Mazzone, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita, Fabrizio Conti, Alessandro Zullo, Lucia Simoni, Martina Fiocchi, Roberto Orsenigo, Delia Colombo. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study. BMC Health Serv Res 2022;22:1537. [PMID: 36527051 DOI: 10.1186/s12913-022-08954-8] [Reference Citation Analysis]
8 Shau WY, Setia S, Shinde SP, Santoso H, Furtner D. Contemporary Databases in Real-world Studies Regarding the Diverse Health Care Systems of India, Thailand, and Taiwan: Protocol for a Scoping Review. JMIR Res Protoc 2022;11:e43741. [PMID: 36512386 DOI: 10.2196/43741] [Reference Citation Analysis]
9 Kuehne F, Arvandi M, Hess LM, Faries DE, Matteucci Gothe R, Gothe H, Beyrer J, Zeimet AG, Stojkov I, Mühlberger N, Oberaigner W, Marth C, Siebert U. Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: systematic bias assessment of ovarian cancer treatment effectiveness. J Clin Epidemiol 2022;152:269-80. [PMID: 36252741 DOI: 10.1016/j.jclinepi.2022.10.005] [Reference Citation Analysis]
10 Santi D, Spaggiari G, Granata ARM, Simoni M. Real-world evidence analysis of the follicle-stimulating hormone use in male idiopathic infertility. Best Pract Res Clin Obstet Gynaecol 2022;85:121-33. [PMID: 35618626 DOI: 10.1016/j.bpobgyn.2022.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sánchez-Iglesias JL, Bebia V, Gimenez E, Aller MB, Bradbury M, Pérez-Benavente MA, Gil-Moreno A, Cossio-Gil Y. Cost analysis of the enhanced recovery after surgery protocol applied in advanced ovarian cancer: A secondary outcome of the PROFAST trial. Eur J Surg Oncol 2022;48:2545-50. [PMID: 35922279 DOI: 10.1016/j.ejso.2022.07.013] [Reference Citation Analysis]
12 Girsh YV, Kiyaev AV, Slovak MA, Korneva IV, Promin IA, Yusupova NA, Savelyev LI. Comparative assessment of modern parameters of glycemic control in children with type 1 diabetes after switching to fast-acting insulin aspart using Flash Glucose Monitoring in real clinical practice. Diabetes mellitus 2022;25:458-467. [DOI: 10.14341/dm12838] [Reference Citation Analysis]
13 Borecka O, Ofori A, Amini F, Llewellyn S. Sickle cell disease: a global patient registry review. Future Rare Diseases 2022. [DOI: 10.2217/frd-2022-0014] [Reference Citation Analysis]
14 Yu C, Wang G, Burge RT, Ye E, Dou G, Li J, Harrison RW, McLean RR, Kerti SJ, Bagel J. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb) 2023;13:187-206. [PMID: 36385699 DOI: 10.1007/s13555-022-00843-6] [Reference Citation Analysis]
15 Wang SV, Sreedhara SK, Bessette LG, Schneeweiss S. Understanding variation in the results of real-world evidence studies that seem to address the same question. J Clin Epidemiol 2022;151:161-70. [PMID: 36075314 DOI: 10.1016/j.jclinepi.2022.08.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shau W, Setia S, Shinde S, Santoso H, Furtner D. Contemporary databases for real-world studies for three diverse healthcare systems in Asia: a scoping review for India, Thailand, and Taiwan (Preprint).. [DOI: 10.2196/preprints.43741] [Reference Citation Analysis]
17 Velummailum RR, Mckibbon C, Brenner DR, Stringer EA, Ekstrom L, Dron L. Data challenges for externally controlled trials: a viewpoint (Preprint).. [DOI: 10.2196/preprints.43484] [Reference Citation Analysis]
18 Wang SV, Pottegård A, Crown W, Arlett P, Ashcroft DM, Benchimol EI, Berger ML, Crane G, Goettsch W, Hua W, Kabadi S, Kern DM, Kurz X, Langan S, Nonaka T, Orsini L, Perez-gutthann S, Pinheiro S, Pratt N, Schneeweiss S, Toussi M, Williams RJ. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force. Value in Health 2022;25:1663-1672. [DOI: 10.1016/j.jval.2022.09.001] [Reference Citation Analysis]
19 Brooks BR, Berry JD, Ciepielewska M, Liu Y, Zambrano GS, Zhang J, Hagan M. Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis. eClinicalMedicine 2022;52:101590. [DOI: 10.1016/j.eclinm.2022.101590] [Reference Citation Analysis]
20 Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer 2022;175:204-13. [PMID: 36148739 DOI: 10.1016/j.ejca.2022.08.024] [Reference Citation Analysis]
21 Fujinaga J, Fukuoka T. A Review of Research Studies Using Data from the Administrative Claims Databases in Japan. Drugs - Real World Outcomes. [DOI: 10.1007/s40801-022-00331-5] [Reference Citation Analysis]
22 Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia 2022;:3331024221123058. [PMID: 36081276 DOI: 10.1177/03331024221123058] [Reference Citation Analysis]
23 Crane G, Lim JCW, Gau CS, Xie J, Chu L. The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendations. Curr Med Res Opin 2022;38:1543-51. [PMID: 35786170 DOI: 10.1080/03007995.2022.2096354] [Reference Citation Analysis]
24 Zah V, Stanicic F, Ruby J, Vukicevic D, Hurley D. Real-world Medicare Healthcare Costs of Patients with Dupuytren's Contracture Treated with Collagenase or Fasciectomy. Plast Reconstr Surg Glob Open 2022;10:e4480. [PMID: 35999874 DOI: 10.1097/GOX.0000000000004480] [Reference Citation Analysis]
25 Dhruva SS, Zhang S, Chen J, Noseworthy PA, Doshi AA, Agboola KM, Herrin J, Jiang G, Yu Y, Cafri G, Collison Farr K, Ervin KR, Ross JS, Coplan PM, Drozda JP Jr. Safety and Effectiveness of a Catheter With Contact Force and 6-Hole Irrigation for Ablation of Persistent Atrial Fibrillation in Routine Clinical Practice. JAMA Netw Open 2022;5:e2227134. [PMID: 35976649 DOI: 10.1001/jamanetworkopen.2022.27134] [Reference Citation Analysis]
26 Rippin G, Ballarini N, Sanz H, Largent J, Quinten C, Pignatti F. A Review of Causal Inference for External Comparator Arm Studies. Drug Saf 2022. [PMID: 35895225 DOI: 10.1007/s40264-022-01206-y] [Reference Citation Analysis]
27 Sarri G. Can Real-World Evidence Help Restore Decades of Health Inequalities by Informing Health Care Decision-Making? Certainly, and Here is How. Front Pharmacol 2022;13:905820. [DOI: 10.3389/fphar.2022.905820] [Reference Citation Analysis]
28 Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA, Darrow JJ. Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. Front Pharmacol 2022;13:913567. [PMID: 35677436 DOI: 10.3389/fphar.2022.913567] [Reference Citation Analysis]
29 Borisov N, Sorokin M, Zolotovskaya M, Borisov C, Buzdin A. Shambhala-2: A Protocol for Uniformly Shaped Harmonization of Gene Expression Profiles of Various Formats. Curr Protoc 2022;2:e444. [PMID: 35617464 DOI: 10.1002/cpz1.444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. Osteoporos Int 2022. [PMID: 35524068 DOI: 10.1007/s00198-022-06413-y] [Reference Citation Analysis]
31 Obermeier PE, Heim A, Biere B, Hage E, Alchikh M, Conrad T, Schweiger B, Rath BA. Linking digital surveillance and in-depth virology to study clinical patterns of viral respiratory infections in vulnerable patient populations. iScience 2022;25:104276. [DOI: 10.1016/j.isci.2022.104276] [Reference Citation Analysis]
32 Kovács S, Kaló Z, Daubner-Bendes R, Kolasa K, Hren R, Tesar T, Reckers-Droog V, Brouwer W, Federici C, Drummond M, Zemplényi AT. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. Health Econ 2022. [PMID: 35322478 DOI: 10.1002/hec.4504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hidalgo-tenorio C, Pasquau J, Vinuesa D, Ferra S, Terrón A, Sanjoaquín I, Payeras A, Martínez OJ, López-ruz MÁ, Omar M, de la Torre-lima J, López-lirola A, Palomares J, Blanco JR, Montero M, García-vallecillos C. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses 2022;14:524. [DOI: 10.3390/v14030524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Di Loreto C, Minarelli V, Nasini G, Norgiolini R, Del Sindaco P. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria. Diabetes Ther 2022;13:551-67. [PMID: 35230650 DOI: 10.1007/s13300-022-01218-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Hogervorst MA, Pontén J, Vreman RA, Mantel-teeuwisse AK, Goettsch WG. Real World Data in Health Technology Assessment of Complex Health Technologies. Front Pharmacol 2022;13:837302. [DOI: 10.3389/fphar.2022.837302] [Reference Citation Analysis]
36 Liu M, Wang W, Wang M, He Q, Li L, Li G, He L, Zou K, Sun X. Reporting of abstracts in studies that used routinely collected data for exploring drug treatment effects: a cross-sectional survey. BMC Med Res Methodol 2022;22:6. [PMID: 34996370 DOI: 10.1186/s12874-021-01482-9] [Reference Citation Analysis]
37 Werther W, Loughlin AM. Post-Approval Regulatory Requirements. Principles and Practice of Clinical Trials 2022. [DOI: 10.1007/978-3-319-52636-2_256] [Reference Citation Analysis]
38 Anderson M, Drummond M, Taylor D, Mcguire A, Carter P, Mossialos E. Promoting innovation while controlling cost: The UK's approach to health technology assessment. Health Policy 2022. [DOI: 10.1016/j.healthpol.2022.01.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Jernigan DA, Hart MC, Dodd KK, Jameson S, Farney T. Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever: A Retrospective Review of First 14 Months in One Clinic. Cureus 2021;13:e20014. [PMID: 34873551 DOI: 10.7759/cureus.20014] [Reference Citation Analysis]
40 Kessler RC, Luedtke A. Pragmatic Precision Psychiatry-A New Direction for Optimizing Treatment Selection. JAMA Psychiatry 2021;78:1384-90. [PMID: 34550327 DOI: 10.1001/jamapsychiatry.2021.2500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
41 Dagenais S, Russo L, Madsen A, Webster J, Becnel L. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. Clin Pharmacol Ther 2022;111:77-89. [PMID: 34839524 DOI: 10.1002/cpt.2480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Gagne JJ, Avorn J, Gatto NM, Mo J, Dal Pan GJ, Raine J, Uzu S, Kesselheim AS, Vokinger KN. Views from Academia, Industry, Regulatory Agencies, and the Legal System. Textbook of Pharmacoepidemiology 2021. [DOI: 10.1002/9781119701101.ch6] [Reference Citation Analysis]
43 Lu ZK, Xiong X, Lee T, Wu J, Yuan J, Jiang B. Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. Front Pharmacol 2021;12:700012. [PMID: 34737696 DOI: 10.3389/fphar.2021.700012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Rao AR, Garai S, Dey S, Peng H. PIKS: A Technique to Identify Actionable Trends for Policy-Makers Through Open Healthcare Data. SN COMPUT SCI 2021;2:477. [DOI: 10.1007/s42979-021-00871-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Herrera Restrepo O. The power of health economics and outcomes research (HEOR) in making decisions that matter. Magna Sci UCEVA 2021;1:23-32. [DOI: 10.54502/msuceva.v1n1a5] [Reference Citation Analysis]
46 Charvériat M, Darmoni SJ, Lafon V, Moore N, Bordet R, Veys J, Mouthon F; SFPT Translational Research in Pharmacology group. Use of real-world evidence in translational pharmacology research. Fundam Clin Pharmacol 2021. [PMID: 34676579 DOI: 10.1111/fcp.12734] [Reference Citation Analysis]
47 Rani Aitha S, Marpaka S, T C, E B, Rani Kasukurthi S. BIG DATA ANALYTICS IN PHARMACOVIGILANCE - A GLOBAL TREND. Asian J Pharm Clin Res 2021. [DOI: 10.22159/ajpcr.2021.v14i10.42765] [Reference Citation Analysis]
48 Ferreira CG, Abadi MD, de Mendonça Batista P, Serra FB, Peixoto RB, Okumura LM, Cerqueira ER. Demographic and Clinical Outcomes of Brazilian Patients With Stage III or IV Non-Small-Cell Lung Cancer: Real-World Evidence Study on the Basis of Deterministic Linkage Approach. JCO Glob Oncol 2021;7:1454-61. [PMID: 34609902 DOI: 10.1200/GO.21.00228] [Reference Citation Analysis]
49 Uemura Y, Shinozaki T, Nomura S, Shibata T. Comment on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment”. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.1974537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Saldarriaga EM, Hauber B, Carlson JJ, Barthold D, Veenstra DL, Devine B. Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment. Value in Health 2021. [DOI: 10.1016/j.jval.2021.09.016] [Reference Citation Analysis]
51 Alcaraz A, Rodríguez-Antolín A, Carballido-Rodríguez J, Castro-Díaz D, Medina-Polo J, Fernández-Gómez JM, Ficarra V, Palou J, Ponce de León Roca J, Angulo JC, Esteban-Fuertes M, Cózar-Olmo JM, Pérez-León N, Molero-García JM, Fernández-Pro Ledesma A, Brenes-Bermúdez FJ, Manasanch J. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients. Sci Rep 2021;11:19401. [PMID: 34588509 DOI: 10.1038/s41598-021-98586-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
52 Zagni E, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, Costanzo A, Pellacani G, Peris K, Bardazzi F, Argenziano G, Ruffolo S, Dapavo P, Carrera C, Fargnoli MC, Parodi A, Romanelli M, Malagoli P, Talamonti M, Megna M, Raspanti M, Paolinelli M, Hansel K, Narcisi A, Conti A, De Simone C, Chessa MA, De Rosa A, Provenzano E, Ortoncelli M, Moltrasio C, Fidanza R, Burlando M, Tonini A, Gaiani FM, Simoni L, Zullo A, Fiocchi M, Colombo D. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Serv Res 2021;21:924. [PMID: 34488749 DOI: 10.1186/s12913-021-06866-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
53 Teneralli RE, Cepeda MS, Kern DM, Novak GP. Individuals who develop drug-resistant epilepsy within a year after initial diagnosis have higher burden of mental and physical diseases one-year prior to epilepsy diagnosis as compared to those whose seizures were controlled during the same interval. Epilepsy Behav 2021;123:108243. [PMID: 34425326 DOI: 10.1016/j.yebeh.2021.108243] [Reference Citation Analysis]
54 Seeger JD, Nunes A, Loughlin AM. Using RWE research to extend clinical trials in diabetes: An example with implications for the future. Diabetes Obes Metab 2020;22 Suppl 3:35-44. [PMID: 32250529 DOI: 10.1111/dom.14021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
55 Patorno E, Schneeweiss S, Wang SV. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. Diabetes Obes Metab 2020;22 Suppl 3:45-59. [PMID: 32250527 DOI: 10.1111/dom.13918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
56 Rahmatian D, Tadrous M. Old dog with new tricks: An introduction to real-world evidence for pharmacists. Am J Health Syst Pharm 2021:zxab261. [PMID: 34153111 DOI: 10.1093/ajhp/zxab261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Hiramatsu K, Barrett A, Miyata Y; PhRMA Japan Medical Affairs Committee Working Group 1. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan. Drugs Real World Outcomes 2021. [PMID: 34148219 DOI: 10.1007/s40801-021-00266-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
58 Lasky T, McMahon AW, Hua W, Forshee R. Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review. Vaccine 2021;39:3814-24. [PMID: 34090699 DOI: 10.1016/j.vaccine.2021.05.071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Lasky T, McMahon AW, Hua W, Forshee R. Methodologic approaches in studies using real-world data to measure pediatric safety and effectiveness of vaccines administered to pregnant women: a scoping review protocol. JBI Evid Synth 2020;18:2164-70. [PMID: 32813442 DOI: 10.11124/JBISRIR-D-19-00266] [Reference Citation Analysis]
60 Mitra S, Jain A, Ting JY, Ben Fadel N, Drolet C, Abou Mehrem A, Soraisham A, Jasani B, Louis D, Lapointe A, Dorling J, Khurshid F, Hyderi A, Kumaran K, Bodani J, Weisz D, Alvaro R, Adie M, Stavel M, Morin A, Bhattacharya S, Kanungo J, Canning R, Ye XY, Hatfield T, Gardner CE, Shah P. Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA). BMJ Open 2021;11:e050682. [PMID: 33952559 DOI: 10.1136/bmjopen-2021-050682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Thurin NH, Bosco-Levy P, Blin P, Rouyer M, Jové J, Lamarque S, Lignot S, Lassalle R, Abouelfath A, Bignon E, Diez P, Gross-Goupil M, Soulié M, Roumiguié M, Le Moulec S, Debouverie M, Brochet B, Guillemin F, Louapre C, Maillart E, Heinzlef O, Moore N, Droz-Perroteau C. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data. BMC Med Res Methodol 2021;21:95. [PMID: 33933001 DOI: 10.1186/s12874-021-01285-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Jaksa A, Wu J, Jónsson P, Eichler HG, Vititoe S, Gatto NM. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. J Comp Eff Res 2021;10:711-31. [PMID: 33928789 DOI: 10.2217/cer-2020-0228] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
63 Mccollam P, Birt J, Hunter T. Health Outcomes Research. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc257] [Reference Citation Analysis]
64 Ghijben P, Petrie D, Zavarsek S, Chen G, Lancsar E. Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients. Pharmacoeconomics 2021;39:741-56. [PMID: 33834425 DOI: 10.1007/s40273-021-01020-x] [Reference Citation Analysis]
65 Franklin JM, Platt R, Dreyer NA, London AJ, Simon GE, Watanabe JH, Horberg M, Hernandez A, Califf RM. When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? Clin Pharmacol Ther 2021. [PMID: 33826756 DOI: 10.1002/cpt.2255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
66 Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA. Real-world evidence to support regulatory decision making: New or expanded medical product indications. Pharmacoepidemiol Drug Saf 2021;30:685-93. [PMID: 33675248 DOI: 10.1002/pds.5222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
67 Chen J, Ho M, Lee K, Song Y, Fang Y, Goldstein BA, He W, Irony T, Jiang Q, van der Laan M, Lee H, Lin X, Meng Z, Mishra-kalyani P, Rockhold F, Wang H, White R. The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.1883474] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
68 Schneeweiss S, Patorno E. Conducting real-world evidence studies on the clinical outcomes of diabetes treatments. Endocr Rev 2021:bnab007. [PMID: 33710268 DOI: 10.1210/endrev/bnab007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
69 Levenson M, He W, Chen J, Fang Y, Faries D, Goldstein BA, Ho M, Lee K, Mishra-kalyani P, Rockhold F, Wang H, Zink RC. Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.1883473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
70 Rognoni C, Bertolani A, Jommi C. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. Clin Drug Investig 2021;41:303-19. [PMID: 33686614 DOI: 10.1007/s40261-021-01000-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
71 Veličković VM, Chadwick P, Rippon MG, Ilić I, McGlone ER, Gebreslassie M, Csernus M, Streit I, Bordeanu A, Kaspar D, Linder J, Smola H. Cost-effectiveness of superabsorbent wound dressing versus standard of care in patients with moderate-to-highly exuding leg ulcers. J Wound Care 2020;29:235-46. [PMID: 32281509 DOI: 10.12968/jowc.2020.29.4.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Ghesquières H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P, Fabbro-Peray P, Bernier A, Belot A, Chartier L, Fornecker LM, Baldi I, Bouabdallah K, Laurent C, Oberic L, Morineau N, Le Gouill S, Morschhauser F, Haioun C, Damaj G, Guidez S, Labouré G, Fitoussi O, Lebras L, Gressin R, Salles G, Ysebaert L, Monnereau A. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort. BMC Public Health 2021;21:432. [PMID: 33653294 DOI: 10.1186/s12889-021-10433-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Junet V, Farrés J, Mas JM, Daura X. CuBlock: a cross-platform normalization method for gene-expression microarrays. Bioinformatics 2021:btab105. [PMID: 33609102 DOI: 10.1093/bioinformatics/btab105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Nitecki R, Ramirez PT, Frumovitz M, Krause KJ, Tergas AI, Wright JD, Rauh-Hain JA, Melamed A. Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2020;6:1019-27. [PMID: 32525511 DOI: 10.1001/jamaoncol.2020.1694] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 35.0] [Reference Citation Analysis]
75 Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, Bartels DB, Kahler KH, Bessette LG, Schneeweiss S. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ 2021;372:m4856. [PMID: 33436424 DOI: 10.1136/bmj.m4856] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
76 Daubner-Bendes R, Kovács S, Niewada M, Huic M, Drummond M, Ciani O, Blankart CR, Mandrik O, Torbica A, Yfantopoulos J, Petrova G, Holownia-Voloskova M, Taylor RS, Al M, Piniazhko O, Lorenzovici L, Tarricone R, Zemplényi A, Kaló Z. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. Front Public Health 2020;8:612410. [PMID: 33490024 DOI: 10.3389/fpubh.2020.612410] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
77 Donatti C, Meisberger R, Doban V, Avgerinou A, Anderson J, Rosenlund M. Future ready real world data for healthcare optimisation and evidence-based decision making (Preprint).. [DOI: 10.2196/preprints.26321] [Reference Citation Analysis]
78 Iglay K, Ritchey ME. Replication and reproducibility. Pragmatic Randomized Clinical Trials 2021. [DOI: 10.1016/b978-0-12-817663-4.00015-5] [Reference Citation Analysis]
79 Werther W, Loughlin AM. Post-Approval Regulatory Requirements. Principles and Practice of Clinical Trials 2021. [DOI: 10.1007/978-3-319-52677-5_256-1] [Reference Citation Analysis]
80 Cragg JJ, Azoulay L, Collins G, De Vera MA, Etminan M, Lalji F, Gershon AS, Guyatt G, Harrison M, Jutzeler C, Kassam R, Kendzerska T, Lynd L, Mansournia MA, Sadatsafavi M, Tong B, Warner FM, Tremlett H. The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. Expert Opin Drug Saf 2021;20:1-8. [PMID: 33170749 DOI: 10.1080/14740338.2021.1849134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation 2021;143:1002-13. [PMID: 33327727 DOI: 10.1161/CIRCULATIONAHA.120.051718] [Cited by in Crossref: 81] [Cited by in F6Publishing: 89] [Article Influence: 27.0] [Reference Citation Analysis]
82 Sarri G, Patorno E, Yuan H, Guo JJ, Bennett D, Wen X, Zullo AR, Largent J, Panaccio M, Gokhale M, Moga DC, Ali MS, Debray TPA. Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. BMJ Evid Based Med 2020:bmjebm-2020-111493. [PMID: 33298465 DOI: 10.1136/bmjebm-2020-111493] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
83 Gao J, Gong Z, Montesano D, Glazer E, Liegner K. "Repurposing" Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years' Experience in One Medical Practice. Antibiotics (Basel) 2020;9:E868. [PMID: 33291557 DOI: 10.3390/antibiotics9120868] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
84 Sieluk J, Haiderali A, Huang M, Yang L, Hirshfield KM. Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010-2016. Future Oncol 2021;17:1039-54. [PMID: 33261515 DOI: 10.2217/fon-2020-0996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Machado-alba JE, Gaviria-mendoza A, Machado-duque ME, Valladales-restrepo LF. Real-World Evidence: Pharmacoepidemiology for Daily Clinical Practice—An Experience from Colombia. Drugs - Real World Outcomes 2020;7:257-259. [DOI: 10.1007/s40801-020-00208-5] [Reference Citation Analysis]
86 Nazha B, Yang JC, Owonikoko TK. Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol 2021;17:965-77. [PMID: 33242257 DOI: 10.2217/fon-2020-0951] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
87 George G, Garmo H, Scailteux LM, Balusson F, De Coster G, De Schutter H, Kuiper JG, Oger E, Verbeeck J, Van Hemelrijck M. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases. Int J Cancer 2021;148:2203-11. [PMID: 33186481 DOI: 10.1002/ijc.33397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
88 Dolgin E. Core Concept: The pandemic is prompting widespread use-and misuse-of real-world data. Proc Natl Acad Sci U S A 2020;117:27754-8. [PMID: 33087564 DOI: 10.1073/pnas.2020930117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
89 Radawski CA, Hammad TA, Colilla S, Coplan P, Hornbuckle K, Freeman E, Smith MY, Sobel RE, Bahri P, Arias AE, Bennett D. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. Pharmacoepidemiol Drug Saf 2020;29:1532-9. [PMID: 33146901 DOI: 10.1002/pds.5167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
90 Luyendijk M, Vernooij RWM, Blommestein HM, Siesling S, Uyl-de Groot CA. Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. Value Health 2020;23:1497-508. [PMID: 33127021 DOI: 10.1016/j.jval.2020.05.008] [Reference Citation Analysis]
91 Junet V, Farrés J, Mas JM, Daura X. CuBlock: A cross-platform normalization method for gene-expression microarrays.. [DOI: 10.1101/2020.10.29.360198] [Reference Citation Analysis]
92 Tarricone R, Ciani O, Torbica A, Brouwer W, Chaloutsos G, Drummond MF, Martelli N, Persson U, Leidl R, Levin L, Sampietro-Colom L, Taylor RS. Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. Expert Rev Med Devices 2020;17:993-1006. [PMID: 32975149 DOI: 10.1080/17434440.2020.1825074] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
93 Thomas FP, Saporta M, Attarian S, Sevilla T, Mascaró RS, Fabrizi GM, Genovese F, Gray A, Bull S, Tanesse D, Rego M, Moore A, Hollett C, Monteiro K, Paoli X, Llewellyn S, Larkin M, Boutalbi Y. Patient-reported impact of Charcot-Marie-Tooth disease: protocol for a real-world digital lifestyle study. Neurodegener Dis Manag 2021;11:21-33. [PMID: 33086913 DOI: 10.2217/nmt-2020-0044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Dhruva SS, Shah ND, Ross JS. Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products. Mayo Clin Proc 2020;95:2609-11. [PMID: 33289654 DOI: 10.1016/j.mayocp.2020.04.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
95 Ross RD, Shi X, Caram MEV, Tsao PA, Lin P, Bohnert A, Zhang M, Mukherjee B. Veridical Causal Inference using Propensity Score Methods for Comparative Effectiveness Research with Medical Claims. Health Serv Outcomes Res Methodol 2021;21:206-28. [PMID: 34040495 DOI: 10.1007/s10742-020-00222-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
96 Soliman RM, Elhaddad A, Oke J, Eweida W, Sidhom I, Ahmed S, Abdelrahman H, Moussa E, Fawzy M, Zamzam M, Zekri W, Hafez H, Sedky M, Abdalla A, Hammad M, Elzomor H, Ahmed S, Awad M, Abdelhameed S, Mohsen E, Shalaby L, Fouad H, Tarek N, Abouelnaga S, Heneghan C. Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt. Int J Cancer 2021;148:1562-74. [PMID: 32997796 DOI: 10.1002/ijc.33321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
97 Orsini LS, Berger M, Crown W, Daniel G, Eichler HG, Goettsch W, Graff J, Guerino J, Jonsson P, Lederer NM, Monz B, Mullins CD, Schneeweiss S, Brunt DV, Wang SV, Willke RJ. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Value Health 2020;23:1128-36. [PMID: 32940229 DOI: 10.1016/j.jval.2020.04.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
98 Cocoros NM, Arlett P, Dreyer NA, Ishiguro C, Iyasu S, Sturkenboom M, Zhou W, Toh S. The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness. Clin Pharmacol Ther 2021;109:1189-96. [PMID: 32911562 DOI: 10.1002/cpt.2045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
99 Lou J, Kc S, Toh KY, Dabak S, Adler A, Ahn J, Bayani DBS, Chan K, Choiphel D, Chua B, Genuino AJ, Guerrero AM, Kearney B, Lin LW, Liu Y, Nakamura R, Pearce F, Prinja S, Pwu RF, Shafie AA, Sui B, Suwantika A, Teerawattananon Y, Tunis S, Wu HM, Zalcberg J, Zhao K, Isaranuwatchai W, Wee HL. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. Int J Technol Assess Health Care 2020;36:474-80. [PMID: 32928330 DOI: 10.1017/S0266462320000628] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
100 Zhang X, Stamey JD, Mathur MB. Assessing the impact of unmeasured confounders for credible and reliable real-world evidence. Pharmacoepidemiol Drug Saf 2020;29:1219-27. [PMID: 32929830 DOI: 10.1002/pds.5117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
101 Orsini LS, Monz B, Mullins CD, Van Brunt D, Daniel G, Eichler HG, Graff J, Guerino J, Berger M, Lederer NM, Jonsson P, Schneeweiss S, Wang SV, Crown W, Goettsch W, Willke RJ. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Pharmacoepidemiol Drug Saf 2020;29:1504-13. [PMID: 32924243 DOI: 10.1002/pds.5079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
102 Piske M, Thomson T, Krebs E, Hongdilokkul N, Bruneau J, Greenland S, Gustafson P, Karim ME, McCandless LC, Maclure M, Platt RW, Siebert U, Socías ME, Tsui JI, Wood E, Nosyk B. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. BMJ Open 2020;10:e036102. [PMID: 32912944 DOI: 10.1136/bmjopen-2019-036102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
103 Chen WW, Lin CW, Huang WI, Chao PH, Gau CS, Hsiao FY. Using real-world evidence for pharmacovigilance and drug safety-related decision making by a resource-limited health authority: 10 years of experience in Taiwan. Pharmacoepidemiol Drug Saf 2020;29:1402-13. [PMID: 32894792 DOI: 10.1002/pds.5084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Yang J, Yang J. Clearing heat and resolving phlegm for acute exacerbation of chronic obstructive pulmonary disease with the syndrome of phlegm-heat obstruction of the lung. J Int Med Res 2020;48:300060520945502. [PMID: 32814490 DOI: 10.1177/0300060520945502] [Reference Citation Analysis]
105 Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine 2020;25:100445. [PMID: 32775971 DOI: 10.1016/j.eclinm.2020.100445] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
106 Gokhale M, Stürmer T, Buse JB. Real-world evidence: the devil is in the detail. Diabetologia 2020;63:1694-705. [PMID: 32666226 DOI: 10.1007/s00125-020-05217-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
107 Rognoni C, Lugli M, Maleti O, Tarricone R. Venous stenting for patients with outflow obstruction and leg ulcers: cost–effectiveness and budget impact analyses. Journal of Comparative Effectiveness Research 2020;9:705-20. [DOI: 10.2217/cer-2020-0030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
108 Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? Adv Ther 2020;37:3040-58. [PMID: 32524498 DOI: 10.1007/s12325-020-01397-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
109 Tarricone R, Rognoni C, Arnoldo L, Mazzacane S, Caselli E. A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis. Pathogens 2020;9:E502. [PMID: 32585922 DOI: 10.3390/pathogens9060502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Thokala P, Dodd P, Baalbaki H, Brennan A, Dixon S, Lowrie K. Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data. Value Health 2020;23:743-50. [PMID: 32540232 DOI: 10.1016/j.jval.2020.02.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
111 Toledano Delgado R, García-Morales I, Parejo-Carbonell B, Jiménez-Huete A, Herrera-Ramirez D, González-Hernández A, Ayuga Loro F, Santamarina E, Toledo M, Ojeda J, Poza JJ, Molins A, Giner P, Estévez María JC, Castro-Vilanova MD, Zurita J, Saiz-Diaz RA, Gómez-Ibañez A, Rodriguez-Uranga J, Gil-Nagel A, Campos D, Sánchez-Larsen Á, Aguilar-Amat Prior MJ, Mauri Llerda JA, Huertas González N, García-Barragán N. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry. Epilepsia 2020;61:1109-19. [PMID: 32511754 DOI: 10.1111/epi.16548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
112 Viswanathan V, Singh KP. Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). Diabetes Technol Ther 2019;21:415-22. [PMID: 31339784 DOI: 10.1089/dia.2019.0052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
113 Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol 2020;34:2566-73. [PMID: 32364296 DOI: 10.1111/jdv.16568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
114 Heinemann K, Imthurn B, Marions L, Gerlinger C, Becker K, Moehner S, Faustmann T. Safety of Dienogest and Other Hormonal Treatments for Endometriosis in Real-World Clinical Practice (VIPOS): A Large Noninterventional Study. Adv Ther 2020;37:2528-37. [PMID: 32301063 DOI: 10.1007/s12325-020-01331-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
115 Daniel C. La recherche clinique à partir d’entrepôts de données. L’expérience de l’Assistance Publique – Hôpitaux de Paris (AP–HP) à l’épreuve de la pandémie de Covid-19. Rev Med Interne 2020;41:303-7. [PMID: 32334860 DOI: 10.1016/j.revmed.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
116 Polak TB, van Rosmalen J, Uyl-de Groot CA. Expanded Access as a source of real-world data: An overview of FDA and EMA approvals. Br J Clin Pharmacol 2020;86:1819-26. [PMID: 32200551 DOI: 10.1111/bcp.14284] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
117 Abdel-rahman O, Spratlin J, Koski S. Vitamin and herbal supplements’ use among patients with advanced gastrointestinal cancers included in eight clinical trials. J Cancer Res Clin Oncol 2020;146:2089-97. [DOI: 10.1007/s00432-020-03201-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
118 Thieffry S, Klein P, Baulac M, Plumb J, Pelgrims B, Steeves S, Borghs S. Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs. Epilepsia 2020;61:595-609. [PMID: 32201951 DOI: 10.1111/epi.16476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
119 Allan V, Ramagopalan SV, Mardekian J, Jenkins A, Li X, Pan X, Luo X. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res 2020;9:603-14. [PMID: 32186922 DOI: 10.2217/cer-2020-0013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 12.7] [Reference Citation Analysis]
120 Burcu M, Dreyer NA, Franklin JM, Blum MD, Critchlow CW, Perfetto EM, Zhou W. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. Pharmacoepidemiol Drug Saf 2020;29:1228-35. [PMID: 32162381 DOI: 10.1002/pds.4975] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
121 Randolph AG, Xu R, Novak T, Newhams MM, Bubeck Wardenburg J, Weiss SL, Sanders RC, Thomas NJ, Hall MW, Tarquinio KM, Cvijanovich N, Gedeit RG, Truemper EJ, Markovitz B, Hartman ME, Ackerman KG, Giuliano JS Jr, Shein SL, Moffitt KL; Pediatric Intensive Care Influenza Investigators from the Pediatric Acute Lung Injury and Sepsis Investigator’s Network. Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness. Clin Infect Dis 2019;68:365-72. [PMID: 29893805 DOI: 10.1093/cid/ciy495] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
122 Damghani T, Sedghamiz T, Sharifi S, Pirhadi S. Critical c-Met-inhibitor interactions resolved from molecular dynamics simulations of different c-Met complexes. Journal of Molecular Structure 2020;1203:127456. [DOI: 10.1016/j.molstruc.2019.127456] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
123 Parody-Rúa E, Rubio-Valera M, Guevara-Cuellar C, Gómez-Lumbreras A, Casajuana-Closas M, Carbonell-Duacastella C, Aznar-Lou I. Economic Evaluations Informed Exclusively by Real World Data: A Systematic Review. Int J Environ Res Public Health 2020;17:E1171. [PMID: 32059593 DOI: 10.3390/ijerph17041171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
124 Misra VP, Danchenko N, Maisonobe P, Lundkvist J, Hunger M. Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia. J Clin Mov Disord 2020;7:2. [PMID: 32071728 DOI: 10.1186/s40734-020-0083-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
125 Zarin DA, Crown WH, Bierer BE. Issues in the registration of database studies. J Clin Epidemiol 2020;121:29-31. [PMID: 31972275 DOI: 10.1016/j.jclinepi.2020.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
126 Solodovnikov A, Sorokina E, Goldina T. Real-world data: from planning to analysis. Med Tech Asses and Choice 2020;41:9. [DOI: 10.17116/medtech2020410319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
127 Kim SC, Schneeweiss S. When Randomized Clinical Trials and Real‐World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. Arthritis Rheumatol 2019;72:4-6. [DOI: 10.1002/art.41092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
128 Salles G, Bachy E, Smolej L, Simkovic M, Baseggio L, Panovska A, Besson H, Healy N, Garside J, Iraqi W, Diels J, Pick-Lauer C, Spacek M, Urbanova R, Lysak D, Hermans R, Lundbom J, Callet-Bauchu E, Doubek M. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. Ann Hematol 2019;98:2749-60. [PMID: 31745601 DOI: 10.1007/s00277-019-03830-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
129 Xia AD, Schaefer CP, Szende A, Jahn E, Hirst MJ. RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design. Drugs Real World Outcomes 2019;6:193-203. [PMID: 31741199 DOI: 10.1007/s40801-019-00167-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
130 Koto PS, Hu SX, Virani K, Simpkin WL, Christian CA, Cao H, Shankar JJS, Phillips SJ. A Cost-Utility Analysis of Endovascular Thrombectomy in a Real-World Setting. Can J Neurol Sci 2020;47:50-60. [PMID: 31587672 DOI: 10.1017/cjn.2019.308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C, Setoguchi S, Raman SR, Chun DS, Stürmer T, Lund JL. Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiol Drug Saf 2019;29:9-17. [DOI: 10.1002/pds.4924] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
132 Gatto NM, Sobel RE, Geier J, Mo J, Bate A, Reynolds RF. The Role of Pharmacoepidemiology in Industry. Pharmacoepidemiology 2019. [DOI: 10.1002/9781119413431.ch7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Depciuch J, Stanek-widera A, Warchulska M, Lange D, Sarwa K, Koziorowska A, Kula M, Cebulski J. Identification of chemical changes in healthy breast tissue caused by chemotherapy using Raman and FTIR spectroscopy: A preliminary study. Infrared Physics & Technology 2019;102:102989. [DOI: 10.1016/j.infrared.2019.102989] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
134 Franklin JM, Pawar A, Martin D, Glynn RJ, Levenson M, Temple R, Schneeweiss S. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clin Pharmacol Ther 2020;107:817-26. [PMID: 31541454 DOI: 10.1002/cpt.1633] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 10.5] [Reference Citation Analysis]
135 Pottegård A, Klungel O, Winterstein A, Huybrechts K, Hallas J, Schneeweiss S, Evans S, Bate A, Pont L, Trifirò G, Smith M, Bourke A. The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. Pharmacoepidemiol Drug Saf 2019;28:1640-1. [PMID: 31642154 DOI: 10.1002/pds.4911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 Adams M, Bassler D, Darlow BA, Lui K, Reichman B, Hakansson S, Norman M, Lee SK, Helenius KK, Lehtonen L, San Feliciano L, Vento M, Moroni M, Beltempo M, Yang J, Shah PS; International Network for EvaluatingOutcomes (iNeo) of Neonates. Preventive strategies and factors associated with surgically treated necrotising enterocolitis in extremely preterm infants: an international unit survey linked with retrospective cohort data analysis. BMJ Open 2019;9:e031086. [PMID: 31615799 DOI: 10.1136/bmjopen-2019-031086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
137 Koto PS, Fahey J, Meier D, Ledrew M, Loring S. Relative effectiveness and cost-effectiveness of the midwifery-led care in Nova Scotia, Canada: A retrospective, cohort study. Midwifery 2019;77:144-54. [DOI: 10.1016/j.midw.2019.07.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
138 Maharaj AD, Holland JF, Scarborough RO, Evans SM, Ioannou LJ, Brown W, Croagh DG, Pilgrim CHC, Kench JG, Lipton LR, Leong T, McNeil JJ, Nikfarjam M, Aly A, Burton PR, Cashin PA, Chu J, Duong CP, Evans P, Goldstein D, Haydon A, Hii MW, Knowles BPF, Merrett ND, Michael M, Neale RE, Philip J, Porter IWT, Smith M, Spillane J, Tagkalidis PP, Zalcberg JR. The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. BMJ Open 2019;9:e031434. [PMID: 31575580 DOI: 10.1136/bmjopen-2019-031434] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
139 Batel-Marques F, Pereira D, Mendes D, Alves C, Penedones A. Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review. BMJ Open 2019;9:e032522. [PMID: 31530624 DOI: 10.1136/bmjopen-2019-032522] [Reference Citation Analysis]
140 Kurki P. Compatibility of immunogenicity guidance by the EMA and the US FDA. Bioanalysis 2019;11:1619-29. [DOI: 10.4155/bio-2018-0243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
141 Durand F, Pavesi M, Cheung R. Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand? J Hepatol 2019;71:240-2. [PMID: 31229271 DOI: 10.1016/j.jhep.2019.05.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
142 Shah PS, Lehtonen L. Net worth of networks: opportunities and potential. Acta Paediatr 2019;108:1374-6. [PMID: 31099026 DOI: 10.1111/apa.14818] [Reference Citation Analysis]
143 da Silva PM, Aguiar C, Morais J. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study. Revista Portuguesa de Cardiologia 2019;38:559-69. [DOI: 10.1016/j.repc.2019.02.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
144 da Silva PM, Aguiar C, Morais J. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study. Revista Portuguesa de Cardiologia (English Edition) 2019;38:559-569. [DOI: 10.1016/j.repce.2019.11.008] [Reference Citation Analysis]
145 Sinnott SJ, Smeeth L, Williamson E, Perel P, Nitsch D, Tomlinson LA, Douglas IJ. The comparative effectiveness of fourth-line drugs in resistant hypertension: An application in electronic health record data. Pharmacoepidemiol Drug Saf 2019;28:1267-77. [PMID: 31313390 DOI: 10.1002/pds.4808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
146 Leitao MM Jr. The change in landscape after a new landmark is constructed: Radical hysterectomy for early cervical cancer and Minimally Invasive Surgery. Gynecol Oncol 2019;153:1-2. [PMID: 30898302 DOI: 10.1016/j.ygyno.2019.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
147 Kuntz RE, Antman EM, Califf RM, Ingelfinger JR, Krumholz HM, Ommaya A, Peterson ED, Ross JS, Waldstreicher J, Wang SV, Zarin DA, Whicher DM, Siddiqi SM, Lopez MH. Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing. NAM Perspect 2019;2019. [PMID: 34532668 DOI: 10.31478/201906b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Daniel G. Building Trust in RWE Will Support Clearer Regulatory Uses. Ther Innov Regul Sci 2019;53:417-9. [PMID: 31213090 DOI: 10.1177/2168479019859948] [Reference Citation Analysis]
149 Gatto NM, Reynolds RF, Campbell UB. A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real-World Evidence for Regulatory Decisions. Clin Pharmacol Ther 2019;106:103-15. [PMID: 31025311 DOI: 10.1002/cpt.1480] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
150 Justo N, Espinoza MA, Ratto B, Nicholson M, Rosselli D, Ovcinnikova O, García Martí S, Ferraz MB, Langsam M, Drummond MF. Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. Value in Health 2019;22:739-49. [DOI: 10.1016/j.jval.2019.01.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
151 Makady A, van Acker S, Nijmeijer H, de Boer A, Hillege H, Klungel O, Goettsch W. Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews. Value Health 2019;22:399-407. [PMID: 30975390 DOI: 10.1016/j.jval.2018.11.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
152 Kessler RC, Bossarte RM, Luedtke A, Zaslavsky AM, Zubizarreta JR. Machine learning methods for developing precision treatment rules with observational data. Behav Res Ther 2019;120:103412. [PMID: 31233922 DOI: 10.1016/j.brat.2019.103412] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
153 Santos WMD, Secoli SR. Economic burden of inpatients infected with Klebsiella pneumoniae carbapenemase. Einstein (Sao Paulo) 2019;17:eGS4444. [PMID: 31116310 DOI: 10.31744/einstein_journal/2019GS4444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
154 Bate A. Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact. Pharmacoepidemiol Drug Saf 2017;26:1013-7. [PMID: 28913965 DOI: 10.1002/pds.4305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
155 Gliklich RE, Leavy MB. Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence. Drug Inf J 2019. [DOI: 10.1177/2168479019837520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Klonoff DC. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. J Diabetes Sci Technol 2020;14:345-9. [PMID: 30862182 DOI: 10.1177/1932296819832661] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
157 Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y. Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infect Dis Ther 2019;8:285-99. [PMID: 30771220 DOI: 10.1007/s40121-019-0234-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Geldof T, Rawal S, Dyck WV, Huys I. Comparative and combined effectiveness of innovative therapies in cancer: a literature review. J Comp Eff Res 2019;8:205-16. [PMID: 30616358 DOI: 10.2217/cer-2018-0131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
159 Tyczynski JE, Kilpatrick R. Real-World Epidemiologic Studies and Patient Registries. Pharmacovigilance: A Practical Approach 2019. [DOI: 10.1016/b978-0-323-58116-5.00006-7] [Reference Citation Analysis]
160 Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes 2018; 9(12): 252-257 [PMID: 30588287 DOI: 10.4239/wjd.v9.i12.252] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
161 Bate A, Chuang-Stein C, Roddam A, Jones B. Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databases. Pharm Stat 2019;18:65-77. [PMID: 30362223 DOI: 10.1002/pst.1908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
162 Wong J, Horwitz MM, Zhou L, Toh S. Using machine learning to identify health outcomes from electronic health record data. Curr Epidemiol Rep 2018;5:331-42. [PMID: 30555773 DOI: 10.1007/s40471-018-0165-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
163 Leonart LP, Tonin FS, Ferreira VL, Fernandez-Llimos F, Pontarolo R. Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine 2019;63:18-26. [PMID: 30145746 DOI: 10.1007/s12020-018-1729-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
164 Raschi E, Poluzzi E, Fadini GP, Marchesini G, De Ponti F. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab 2018;20:2711-23. [PMID: 30003655 DOI: 10.1111/dom.13468] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
165 Villanueva V, Montoya J, Castillo A, Mauri-Llerda JÁ, Giner P, López-González FJ, Piera A, Villanueva-Hernández P, Bertol V, Garcia-Escrivá A, Garcia-Peñas JJ, Garamendi I, Esteve-Belloch P, Baiges-Octavio JJ, Miró J, Falip M, Garcés M, Gómez A, Gil-López FJ, Carreño M, Rodriguez-Uranga JJ, Campos D, Bonet M, Querol R, Molins A, Tortosa D, Salas-Puig J. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. Epilepsia 2018;59:1740-52. [PMID: 30062784 DOI: 10.1111/epi.14522] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 11.6] [Reference Citation Analysis]
166 Rohracher A, Zimmermann G, Villanueva V, Garamendi I, Sander JW, Wehner T, Shankar R, Ben-menachem E, Brodie MJ, Pensel MC, Di Gennaro G, Maurousset A, Strzelczyk A, Rheims S, Rácz A, Menzler K, Bertol-alegre V, García-morales I, López-gonzález FJ, Toledo M, Carpenter KJ, Trinka E. Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia 2018;59:1727-39. [DOI: 10.1111/epi.14520] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
167 Maissenhaelter BE, Woolmore AL, Schlag PM. Real-world evidence research based on big data: Motivation-challenges-success factors. Onkologe (Berl) 2018;24:91-8. [PMID: 30464373 DOI: 10.1007/s00761-018-0358-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
168 Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M; joint ISPE-ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiol Drug Saf 2017;26:1018-32. [PMID: 28913963 DOI: 10.1002/pds.4295] [Cited by in Crossref: 87] [Cited by in F6Publishing: 97] [Article Influence: 17.4] [Reference Citation Analysis]
169 Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033-1039. [PMID: 28913966 DOI: 10.1002/pds.4297] [Cited by in Crossref: 176] [Cited by in F6Publishing: 185] [Article Influence: 35.2] [Reference Citation Analysis]
170 Maissenhälter BE, Woolmore AL, Schlag PM. Real-World-Evidence-Forschung auf Basis von Big Data. Onkologe 2018;24:378-389. [DOI: 10.1007/s00761-018-0354-7] [Reference Citation Analysis]
171 Wang SV, Kulldorff M, Glynn RJ, Gagne JJ, Pottegård A, Rothman KJ, Schneeweiss S, Walker AM. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf 2018;27:567-9. [PMID: 29701279 DOI: 10.1002/pds.4442] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
172 Abou-El-Enein M, Grainger DW, Kili S. Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. Mol Ther 2018;26:1172-6. [PMID: 29685384 DOI: 10.1016/j.ymthe.2018.04.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
173 Machado MAÁ, Moura CS, Guerra SF, Curtis JR, Abrahamowicz M, Bernatsky S. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther 2018;20:60. [PMID: 29566769 DOI: 10.1186/s13075-018-1539-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
174 Berdaï D, Thomas-Delecourt F, Szwarcensztein K, d'Andon A, Collignon C, Comet D, Déal C, Dervaux B, Gaudin AF, Lamarque-Garnier V, Lechat P, Marque S, Maugendre P, Méchin H, Moore N, Nachbaur G, Robain M, Roussel C, Tanti A, Thiessard F; table ronde « recherche clinique et méthodologie » des Ateliers de Giens XXXIII. Demandes d’études post-inscription (EPI), suivi des patients en vie réelle : évolution de la place des bases de données. Therapie 2018;73:1-12. [PMID: 29499906 DOI: 10.1016/j.therap.2017.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
175 Yang SC, Lin CC, Lai WW, Chang SM, Hwang JS, Su WC, Wang JD. Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Ther Adv Med Oncol 2018;10:1758834018755072. [PMID: 29434678 DOI: 10.1177/1758834018755072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
176 Berdaï D, Thomas-delecourt F, Szwarcensztein K, d’Andon A, Collignon C, Comet D, Déal C, Dervaux B, Gaudin A, Lamarque-garnier V, Lechat P, Marque S, Maugendre P, Méchin H, Moore N, Nachbaur G, Robain M, Roussel C, Tanti A, Thiessard F. Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases. Therapies 2018;73:13-24. [DOI: 10.1016/j.therap.2017.12.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
177 Khosla S, White R, Medina J, Ouwens M, Emmas C, Koder T, Male G, Leonard S. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? F1000Res 2018;7:111. [PMID: 30026923 DOI: 10.12688/f1000research.13585.2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 9.6] [Reference Citation Analysis]
178 Kurz X, Perez-Gutthann S; ENCePP Steering Group. Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Pharmacoepidemiol Drug Saf 2018;27:245-52. [PMID: 29327451 DOI: 10.1002/pds.4381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
179 Bate A, Reynolds RF, Caubel P. The hope, hype and reality of Big Data for pharmacovigilance. Ther Adv Drug Saf 2018;9:5-11. [PMID: 29318002 DOI: 10.1177/2042098617736422] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
180 Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value in Health 2017;20:1009-22. [DOI: 10.1016/j.jval.2017.08.3018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]